Business Wire

IBSA

4.8.2022 13:02:07 CEST | Business Wire | Press release

Share
The IBSA Class40 – the Craft That Will Take Alberto Bona to the Route Du Rhum – Was Launched in Trinité-Sur-Mer

Latest-generation Class40, “scow” bow, five months of production: the IBSA craft with which Alberto Bona will participate in the Route du Rhum in November was launched yesterday in La Trinité-Sur-Mer (Brittany, France). It’s the first project of the three-year program Sailing into the Future. Together that the ocean sailor started in early 2022, together with the Swiss pharmaceutical company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005581/en/

Designed by Sam Manuard , one of the great French naval architects when it comes to ocean classes, the IBSA Class40 was built by the JPS Production shipyard. It’s a Mach 5 model, the latest evolution of Manuard’s Class40, and will be present at the start of the Route du Rhum as one of the most innovative and modern boats. Much attention will surely be drawn to the rounded bow, created with the aim of increasing performance when sailing downwind, but also the hull promises high performance, thanks to the shape of the water lines and appendages, designed to make it a fast all-rounder when reaching too. Distinctive is also the design of the cockpit, large and well protected: a choice that will allow the sailor to face navigation in the most comfortable and safe positions possible. “This boat perfectly reflects our approach to the program ”, summarised Alberto Bona . “It’s the result of the search for detail, of the improvement in every single aspect: we were looking for a fast hull, clearly at the limits of the box rule, reliable in all weather conditions and sufficiently innovative to make a difference ”.

The project Sailing into the Future. Together started from scratch last January with a partnership – that between IBSA and Alberto Bona – born on common grounds and values, with the aim of using sailing as a corporate communication vehicle towards the market and the nautical world. “Ingenuity, courage, innovation, responsibility are elements which unite us - explained Bona - for this reason we are facing together this challenge, which is clearly sporting but which also metaphorically represents the Company's history, philosophy and vision always turned towards the future, and is part of a path bringing IBSA ever closer to environmental and social sustainability, inclusion and integration. In this type of challenge, the solitary navigator stands out but, as in the industry, the commander exists as a function of his team. With IBSA, we first of all built a team ”.

As for the team , we start with Sidney Gavignet as a coach: the very experienced French navigator laid the foundations and objectives, with a strict rule: always be prepared, to foresee all aspects of the challenge, on land and at sea. “Sidney put us in a position to divide this great challenge into many small steps. A long roadmap of stages to be reached, training and testing in preparation for the start, since building a challenge like the Route du Rhum from scratch in seven months is extremely demanding ”. For the physical preparation part, Bona relied on Andrea Madaffari : he has been working with him for months on endurance and strength, as well as on the management of the energy peaks necessary during a regatta. “When sailing, one needs stamina and does a lot of pulling and hauling: you pull sheets and halyards, you need endurance and peak strength ”, explained Bona . “We are working on this, as well as on the aerobic part ”.

The choice of Sam Manuard as a designer was virtually natural ,” recalled Bona , and is based on a solid relationship dating back to the time of the Mini class, on the sharing of a design vision and on the innovations that Bona was looking for his IBSA Class40. On the sails front, Bona chose Remi Aubrum , whom he entrusted with the choice of innovative materials, compatible with the rigorous box rule of the Class40. The last operational entry is that of the Boat Captain, the Breton expert Pierre-Edouard Regaud .

In recent months we have all been working with the same philosophy, that of the goals to be achieved day by day. We are working on fatigue management, on finding the best solutions in all aspects of the project. It was a huge team effort, between us and IBSA , that led us to yesterday’s technical launch, said Bona .

In the afternoon, at 5 pm, the IBSA Class40 made on board a truck the short journey between the shipyard and the marina that will host it, which is located in front of “Casa IBSA”, the operational headquarters . Alberto Bona now has one month to set up the boat and to qualify, by sailing a thousand miles by the end of August. On September 9, the actual launch – the ceremony that will officially make the Class40 enter the IBSA world – will take place in La Trinité-sur-Mer . In mid-September, Bona will participate in the Malouine Lamotte regatta; then, he will transfer his operational base to Saint-Malo, from where the first regatta of the three-year program will start.

We will talk to sailing enthusiasts and to the entire IBSA world, ” explained Bona , who also underlines the existence of a comprehensive sustainability project, in common with IBSA : “Navigators are experts in circular economy; they live for long periods on the ocean, they replace fossil fuels with solar and wind energy, they recycle everything they can, they live in true harmony with the sea, that they help protect: this is a very important message that, together with IBSA, we wish to promote and share, using the solo oceanic challenge as a great metaphor of what can and must be done for the environment ”.

In its program associated with sailing, IBSA is also committed to inclusiveness: in fact, the inclusive sailing project involving the Associazione Velabili based at the Circolo Velico Lago di Lugano (Switzerland), the Société des Régates d’Antibes (France) and the Yacht Club Punta Ala (Italy) has also been activated. The project aims to support inclusive sailing by promoting initiatives involving people with disabilities in experiences in contact with the sea and the sailing world, and consists in supporting a team of disabled sailors in participating in the Special Olympics World Games of 2023 and in the purchase of Hansa 303 boats for the Clubs of Punta Ala and Antibes.

IBSA

IBSA (Institut Biochimique SA ) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.

Link:

ClickThru

Social Media:

https://www.facebook.com/ibsapharma

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye